Meet our team this coming AASLD on Nov 11 to Nov 14 in Boston, MA
We’re excited to announce that Fibronostics will be attending AASLD on 11.10-11.14 in Boston, MA! We will be presenting 5 posters and can’t wait to network
Fibronostics joining forces with Stone diagnostics for Enhanced Laboratory services
We are proud to announce today of our strategic partnership with STONE Diagnostics, a leading provider of laboratory services in the United States. STONE Diagnostics will provide
Fibronostics will be at the EASL2023 congress in Vienna!
Fibronostics will be guests at the EASL congress in Vienna, Austria to present ‘NAFLD: Diagnostics and non-invasive assessment’. Join Dr. Mona Munteanu, our Chief Scientific Officer, on 24 June
What is a Liver Blood Test?
Also known as a liver function test (LFT) or a liver panel test, a liver blood test is used to diagnose and monitor liver disease.
AASLD Poster: Long-term prognosis of patients with metabolic dysfunction – associated fatty liver disease by non-invasive methods.
AASLD Poster: Long-term prognosis of patients with metabolic dysfunction – associated fatty liver disease by non-invasive methods.
Fibronostics is proud to announce today that it has secured $6.5 million in funding. In addition – Sven Henrichwark, PhD, has been named the company’s new CEO.
NEW YORK and SINGAPORE, June 15, 2022 /PRNewswire/ — Fibronostics, a global leader in non-invasive, AI-driven diagnostics for NASH patients, announced today it has secured $6.5 million in funding. In addition to
